Sharda Cropchem Ltd

- There is no mention of any current or planned fundraising through debt or equity in the call transcript. - The company remains net debt-free as of December 31, 2025, with cash and bank liquid investments of INR 826 crores. - The company is planning capital expenditure of INR 450-500 crores for FY '27, but no mention of raising funds for this capex via debt or equity. - Management indicated focus on increasing dividend payout but stated they are not looking at acquisitions, which often require external funding. - Overall, no indication of any fundraising plans through debt or equity was provided in the call.

- Planned capital expenditure (capex) for FY '26 is around INR 500 crores, with INR 399 crores already spent in the first 9 months. - Capex is aimed at supporting a strong project pipeline, focusing on growth and resilience. - For FY '27, capex guidance is estimated to be in the range of INR 450 crores to INR 500 crores, though it could be higher due to uncertainties. - The capex primarily supports increasing the global registration pipeline of approximately 1,070 products. - Registration timelines are uncertain and can vary widely from 1 year to up to 6-7 years. - The company is not currently looking at acquisitions but is considering increasing dividend payouts instead.

- Expected volume growth of around 15% in FY '27. - Revenue growth anticipated between 15% to 20% in FY '27. - Q4 FY '26 projected as the strongest quarter with demand growth continuing. - Growth driven by both new dealers and expanded geographic reach, especially in Europe. - Price levels expected to improve gradually, supporting better margins. - Strong pipeline with 1,076 product registrations in approval, supporting sustained future growth. - Continued focus on increasing registrations and market penetration within key regions (Europe, NAFTA, LATAM). - Capex planned in the range of INR 450-500 crores to support growth and registration activities.

- The company expects volume growth of around 15% for FY '27. - Revenue growth is anticipated to be in the range of 15% to 20% for FY '27. - Gross margins of approximately 35% are sustainable and may even improve further in FY '27. - EBITDA margins are expected to be maintained in the range of 18% to 20%. - The company shows confidence in sustaining healthy EBITDA margins and improving overall profitability. - PAT has demonstrated strong growth (366% YoY in Q3 FY '26) and the company aims to sustain growth momentum. - Price realizations and product mix improvements are contributing to rising margins and revenues. - Management expects gradual price increases, supporting better margins going forward. - Dividend payouts are being considered for increase, indicating strong cash generation.

- As of December 31, 2025, Sharda Cropchem's total product registrations stand at 3,004 globally. - There are 1,076 product registration applications currently in the approval pipeline. - Regional breakup of pending registrations: Europe - 698, NAFTA - 100, LATAM - 153, Rest of the World - 125. - Registration process timelines are uncertain; can range from 1-2 years to even 6-7 years due to regulatory complexities. - The company is investing around INR 400-500 crores capex towards expanding registration pipeline and related capacities. - These registrations form a critical part of their order book for future revenue growth and market expansion.